Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Mar 16, 2023; 15(3): 177-190
Published online Mar 16, 2023. doi: 10.4253/wjge.v15.i3.177
Published online Mar 16, 2023. doi: 10.4253/wjge.v15.i3.177
Endoscopic biliary treatment of unresectable cholangiocarcinoma: A meta-analysis of survival outcomes and systematic review
Jeffrey Rebhun, Department of Gastroenterology, Oregon Health and Sciences University, Portland, OR 97239, United States
Claire M Shin, Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, United States
Uzma D Siddiqui, Center for Endoscopic Research and Therapeutics, University of Chicago, University of Chicago Medicine, Chicago, IL 60637, United States
Edward Villa, Department of Gastroenterology and Hepatology, Northshore University Health System, Evanston, IL 60201, United States
Author contributions: Villa E contributed to conception and design; Rebhun J and Villa E contributed to analysis and interpretation of the data; Rebhun J, Shin CM, Villa E contributed to drafting of the article; Siddiqui UD and Villa E contributed to critical revision of the article for important intellectual content; Rebhun J, Shin CM, Siddiqui UD, Villa E contributed to final approval of the article.
Conflict-of-interest statement: Uzma Siddiqui has served as a speaker/consultant for Boston Scientific, Medtronic, and Olympus. Edward Villa has served as a consultant/speaker for ConMed as well as a speaker for Ovesco.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jeffrey Rebhun, MD, Academic Fellow, Department of Gas troenterology, Oregon Health and Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, United States. jeffrebhun@gmail.com
Received: November 3, 2022
Peer-review started: November 3, 2022
First decision: December 11, 2022
Revised: January 12, 2023
Accepted: March 1, 2023
Article in press: March 1, 2023
Published online: March 16, 2023
Processing time: 132 Days and 9.9 Hours
Peer-review started: November 3, 2022
First decision: December 11, 2022
Revised: January 12, 2023
Accepted: March 1, 2023
Article in press: March 1, 2023
Published online: March 16, 2023
Processing time: 132 Days and 9.9 Hours
Core Tip
Core Tip: Endoscopic radiofrequency ablation offers endoscopists a reasonable palliative method by which to treat patients with unresectable cholangiocarcinoma that results in longer survival as compared to biliary stenting alone, percutaneous radiofrequency ablation, with biliary stenting, and photodynamic therapy with biliary stenting.